Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/annonc/mdl351 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Osteoporosis in men-East and West: Can the twain meet? A perspective from Asia.
Osteoporos Sarcopenia
December 2024
Osteoporosis and Bone Metabolism Unit, Department of Endocrinology, Singapore General Hospital, Singapore.
Osteoporosis in men remains a significantly underrecognized condition, with notable differences in bone mineral density (BMD) and fracture risk between Asian and Western populations. Despite 30% of hip fractures globally occurring in men, they are less likely to be diagnosed or treated for osteoporosis, especially in resource-limited settings. Given these disparities, a deeper understanding of osteoporosis epidemiology and treatment efficacy in men is essential, particularly in Asian populations.
View Article and Find Full Text PDFCost-effectiveness intervention thresholds for romosozumab and teriparatide in the treatment of osteoporosis in the UK.
Osteoporos Int
December 2024
Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.
Unlabelled: Sequential romosozumab-to-alendronate or sequential teriparatide-to-alendronate can be a cost-effective treatment option for postmenopausal women at very high risk of fracture.
Purpose: To estimate the 10-year probability of a major osteoporotic fracture (MOF) at which sequential treatment with romosozumab or teriparatide followed by alendronate, compared with alendronate alone, becomes cost-effective in a UK setting.
Methods: A microsimulation model with a Markov structure was used to simulate fractures, costs, and quality-adjusted life years (QALYs), in women receiving sequential treatment with either romosozumab or teriparatide followed by alendronate, compared with alendronate alone.
Minodronate for severe multiple vertebral fractures due to pregnancy- and lactation-associated osteoporosis: a case report and literature review.
Ther Adv Musculoskelet Dis
July 2024
Fukushima Medical Center for Children and Women, Fukushima Medical University, 1 Hikarigaoka, Fukushima City, Fukushima 960-1295, Japan.
Pregnancy- and lactation-associated osteoporosis (PLO) is a rare type of premenopausal osteoporosis, typically occurring during the third trimester of pregnancy and the early postpartum lactation period. This report presents a case involving severe multiple vertebral fractures due to PLO with low bone mineral density (BMD) and heightened bone turnover. A 39-year-old primiparous Japanese woman reported low back pain (LBP) starting at 28 weeks of pregnancy.
View Article and Find Full Text PDFRecommendations for the optimal use of bone forming agents in osteoporosis.
Aging Clin Exp Res
August 2024
University Vita-Salute San Raffaele, Milan, Italy.
Article Synopsis
- Bone forming agents are important treatments for people with osteoporosis who have a very high risk of getting fractures.
- Doctors need to identify the right patients who will benefit the most from these treatments, especially those with severe osteoporosis or recent fractures.
- Using these agents can help strengthen bones and reduce fracture risk, and after treatment, patients should switch to other therapies to keep their bones strong.
Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study.
Health Technol Assess
April 2024
School of Medicine, University of Nottingham, Nottingham, UK.
Background: Bisphosphonates are a class of medication commonly used to treat osteoporosis. Alendronate is recommended as the first-line treatment; however, long-term adherence (both treatment compliance and persistence) is poor. Alternative bisphosphonates are available, which can be given intravenously and have been shown to improve long-term adherence.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!